Phreesia (PHR) Company Report

PharmaEssentia will present at the 44th Annual J.P. Morgan Healthcare Conference on Thursday, January 15.
The company reported strong commercial growth for BESREMi® in polycythemia vera in 2025, with Q3 2025 revenue of $127.8 million, representing 44% year-over-year growth.
In 2025, PharmaEssentia submitted the BESREMi® injection pen to the FDA and a supplemental Biologics License Application (BLA) for label expansion to include essential thrombocythemia (ET).
Key anticipated milestones for 2026 include the U.S. launch of BESREMi Pen™ (H1 2026) and potential FDA approval and commercial launch of the ET indication (H2 2026).
The company also advanced six high-value programs to the IND-enabling stage in 2025 and plans to file IND submissions for multiple earlier-stage pipeline programs in 2026.

Dec 15, 2025, 1:00 PM

Press Release

Phreesia Reports Strong Q3 2026 Results, Updates FY2026 Guidance, and Provides FY2027 Outlook

PHR

Earnings

Guidance Update

M&A

Phreesia reported Q3 Fiscal 2026 revenue of $120.3 million, a 13% year-over-year increase, with Adjusted EBITDA reaching $29.1 million and an all-time high margin of 24%.
The company achieved positive net income of $4.3 million for the second consecutive quarter and positive operating cash flow ($15.5 million) and free cash flow ($8.8 million) for five consecutive quarters.
Phreesia updated its Fiscal Year 2026 revenue outlook to $479 million-$481 million and Adjusted EBITDA outlook to $99 million-$101 million, incorporating $7.5 million in revenue contribution from the recently closed AccessOne acquisition.
For Fiscal Year 2027, the company introduced an initial outlook projecting revenue between $545 million-$559 million and Adjusted EBITDA between $125 million-$135 million, with AccessOne expected to contribute approximately 6.5% of total revenue.
Strategic growth initiatives include expanding into provider financing through the AccessOne acquisition and developing new healthcare provider (HCP) marketing offerings, which are expected to add a durable differentiated revenue stream.

Dec 8, 2025, 10:00 PM

Transcript

Phreesia Reports Q3 FY2026 Results, Updates Outlook, and Completes AccessOne Acquisition

PHR

Earnings

Guidance Update

M&A

Phreesia reported Q3 FY2026 total revenue of $120.3 million, representing a 13% year-over-year increase, with Adjusted EBITDA of $29 million and net income of $4.3 million.
The company completed the acquisition of AccessOne on November 12, 2025, for a purchase price of $160 million in cash, funded by a mix of cash and a $110 million secured term loan.
For Fiscal Year 2026, Phreesia provided an outlook of total revenue between $479 million and $481 million and Adjusted EBITDA between $99 million and $101 million.
Looking ahead to Fiscal Year 2027, the company anticipates total revenue between $545 million and $559 million and Adjusted EBITDA between $125 million and $135 million.

Dec 8, 2025, 10:00 PM

Presentation

Phreesia Reports Strong Q3 Fiscal 2026 Results and Updates Full-Year Guidance

PHR

Earnings

Guidance Update

M&A

Phreesia reported strong Q3 Fiscal 2026 results, with revenue of $120.3 million, a 13% increase year-over-year, and an all-time high Adjusted EBITDA margin of 24% for the quarter ended October 31, 2025.
The company updated its Fiscal Year 2026 revenue outlook to $479 million-$481 million and Adjusted EBITDA outlook to $99 million-$101 million, incorporating contributions from the recently closed AccessOne acquisition.
For Fiscal Year 2027, Phreesia provided an initial outlook projecting revenue between $545 million-$559 million and Adjusted EBITDA between $125 million-$135 million.
Phreesia is strategically expanding into provider financing via the AccessOne acquisition and developing Healthcare Provider (HCP) marketing as new growth levers and differentiated revenue streams.

Dec 8, 2025, 10:00 PM

Transcript

Phreesia Reports Strong Q3 Fiscal 2026 Results and Updates Fiscal 2026/2027 Outlook

PHR

Earnings

Guidance Update

M&A

Phreesia reported Q3 Fiscal 2026 revenue of $120.3 million, a 13% increase year-over-year, and Adjusted EBITDA of $29.1 million, achieving an all-time high margin of 24%. The company also recorded net income of $4.3 million for the second consecutive quarter and positive operating and free cash flow for the fifth consecutive quarter.
The company updated its Fiscal Year 2026 revenue outlook to a range of $479 million - $481 million and Adjusted EBITDA outlook to $99 million - $101 million. This updated outlook includes approximately $7.5 million in revenue contribution from the AccessOne acquisition between its closing date (November 12th) and the fiscal year-end.
For Fiscal Year 2027, Phreesia introduced an initial outlook, projecting revenue between $545 million and $559 million and Adjusted EBITDA between $125 million and $135 million. AccessOne is anticipated to contribute approximately 6.5% of the total fiscal 2027 revenue outlook.
Phreesia is expanding into new growth areas, including provider financing through the AccessOne acquisition and healthcare provider (HCP) marketing, leveraging its existing platform and acquisitions like MediFind and PhreesiaOnCall.

Dec 8, 2025, 10:00 PM

Transcript

Phreesia Announces Q3 Fiscal 2026 Results and Updates Fiscal 2026 Outlook

PHR

Earnings

Guidance Update

M&A

Phreesia reported total revenue of $120.3 million for the fiscal third quarter ended October 31, 2025, an increase of 13% year-over-year, with net income of $4.3 million and Adjusted EBITDA of $29.1 million.
The company generated $8.8 million in free cash flow and held $106.4 million in cash and cash equivalents as of October 31, 2025.
Phreesia completed the acquisition of AccessOne for approximately $160 million on November 12, 2025, funded by cash and a new $110 million secured term loan.
The fiscal 2026 revenue outlook was updated to a range of $479 million to $481 million, including approximately $7.5 million from AccessOne, and the Adjusted EBITDA outlook was raised to $99 million to $101 million.
The fiscal 2026 expectation for Average Number of Healthcare Services Clients (AHSCs) was updated to approximately 4,515, incorporating 15 AHSCs from the AccessOne acquisition.

Dec 8, 2025, 9:03 PM

Press Release

Phreesia Announces Q3 Fiscal 2026 Results and Introduces Fiscal 2027 Outlook

PHR

Earnings

Guidance Update

M&A

Phreesia reported total revenue of $120.3 million for the fiscal third quarter ended October 31, 2025, marking a 13% year-over-year increase. The company achieved a net income of $4.3 million and Adjusted EBITDA of $29.1 million for the quarter.
The company completed the acquisition of AccessOne on November 12, 2025, for approximately $160 million in cash, funded by a combination of cash and a $110 million secured term loan. AccessOne is expected to contribute approximately $35 million of annualized revenue and $11 million of annualized Adjusted EBITDA.
Phreesia updated its fiscal 2026 revenue outlook to a range of $479 million to $481 million and its Adjusted EBITDA outlook to $99 million to $101 million, including contributions from AccessOne.
For fiscal 2027, the company introduced a revenue outlook of $545 million to $559 million, representing a 14-16% increase over the fiscal 2026 outlook, and an Adjusted EBITDA outlook of $125 million to $135 million.

Dec 8, 2025, 9:02 PM

8-K

Phreesia Completes AccessOne Acquisition and Secures Bridge Loan

PHR

M&A

Debt Issuance

New Projects/Investments

Phreesia, Inc. completed the acquisition of AccessOne Parent Holdings, Inc. on November 12, 2025.
The acquisition consideration for AccessOne's equityholders was approximately $163 million in cash, subject to customary purchase price adjustments.
The purchase price was funded by $107 million in net proceeds from a bridge loan, $50 million from Phreesia's cash balance, and $6 million in cash acquired from AccessOne.
A $110,000,000 bridge term loan facility was established with Goldman Sachs Bank USA to help finance the acquisition.

Nov 12, 2025, 10:18 PM

8-K

Qualifacts Named to Top 25 Healthcare Software Companies of 2025 List

PHR

Product Launch

New Projects/Investments

Qualifacts has been recognized by The Healthcare Technology Report as one of the Top 25 Healthcare Software Companies of 2025.
This honor comes during a year of significant growth and product momentum for Qualifacts, fueled by the rapid adoption of its AI-powered Qualifacts iQ suite.
In 2025, Qualifacts became the first behavioral health EHR vendor to achieve ISO 42001:2023 certification, meeting global standards for AI governance, transparency, and compliance.
Its AI solutions include Qualifacts iQ Assistant, launched in July 2025 and adopted by nearly 450 organizations, and Qualifacts iQ Clinical Documentation, launched in 2024 and used by over 160 organizations.

Oct 14, 2025, 1:55 PM

Press Release

Earnings Transcripts

Quarterly earnings call transcripts for Phreesia.

Q3 2026

Dec 8, 2025

→

Q2 2026

Sep 4, 2025

→

Q1 2026

May 28, 2025

→

View All Transcripts

Ask Fintool AI Agent

Get instant answers from SEC filings, earnings calls & more

What did Chaim Indig say about margins?What are Phreesia's strategic priorities?How is Phreesia positioned vs competitors?How did Phreesia do last quarter?

Phreesia (PHR)

Analyst Earnings Quarterly Reports

Q1 2026

Q4 2025

Q3 2025

Q2 2025

Executives

Chaim Indig

Allison Hoffman

Amy Beth VanDuyn

Balaji Gandhi

David Linetsky

Evan Roberts

Board Members

Edward Cahill

Gillian Munson

Lainie Goldstein

Lisa Egbuonu-Davis

Mark Smith

Michael Weintraub

Ramin Sayar

Analyst Coverage

Daniel Grosslight

Jailendra Singh

Jessica Tassan

Richard Close

Scott Schoenhaus

Jeffrey Garro

Ryan MacDonald

Jared Haase

Joe Vruwink

John Ransom

Ryan Daniels

Sean Dodge

Brian Tanquilut

Gene Mannheimer

Aaron Kimson

Anne McCormick

Clark Wright

Jeff Garro

Steven Valiquette

Will Jellison

Anne Samuel

Brian Tanquelet

Glen Santangelo

Jack Wallace

Matthew Shea

Matt Shah

Stephanie Davis

Latest news

Earnings Transcripts

Q3 2026

Q2 2026

Q1 2026

Ask Fintool AI Agent